Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer

OBJECTIVE: Treatment options for metastatic castration resistant prostate cancer (mCRPC) have expanded rapidly in recent years. Given the significant economic burden, we sought perform a cost-effectiveness analysis (CEA) of the contemporary treatment paradigm for mCRPC. METHODS: We devised a treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollard, Matthew E., Moskowitz, Alan J., Diefenbach, Michael A., Hall, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730904/
https://www.ncbi.nlm.nih.gov/pubmed/29264205
http://dx.doi.org/10.1016/j.ajur.2016.11.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730904/
https://www.ncbi.nlm.nih.gov/pubmed/29264205
http://dx.doi.org/10.1016/j.ajur.2016.11.005

Ejemplares similares